Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old

Leukemia Research

Volumn 28, Issue 9, 2004, Pages 909-919

  Parmar, Simrit ^a   Rundhaugen, Lynn M ^a   Boehlke, Larry ^a   Riley, MaryBeth ^a   Nabhan, Chadi ^a   Raji, Adekunle ^a   Frater, John L ^a   Tallman, Martin S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

AML; Arsenic; Elderly; Secondary AML

Indexed keywords

ARSENIC TRIOXIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG SCREENING; FATIGUE; FEMALE; FEVER; FOLLICULITIS; HEMATOMA; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; HYPOTENSION; INFECTION; LEUKEMIA; LEUKOPENIA; LUNG DISEASE; LUNG INFILTRATE; MALE; MELENA; MENTAL DISEASE; METASTASIS; MORTALITY; MUCOSA INFLAMMATION; MUSCLE WEAKNESS; MYALGIA; NAUSEA; PAIN; PERICARDIAL EFFUSION; PETECHIA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; QT PROLONGATION; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TOXICITY; URINARY URGENCY; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ARSENICALS; BONE MARROW EXAMINATION; DISEASE PROGRESSION; DRUG RESISTANCE, MULTIPLE; FEMALE; GLYCOPROTEINS; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; OXIDES; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 3242689062     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2003.12.012     Document Type: Article

References (78)

1. Estey EH, Kantarjian H, Keating MJ. Therapy for Acute Myeloid Leukemia. In: Hoffman R, Benz EJ, Shattil SJ, editors. Hematology basic principles and practice. 3rd ed. New York, NY: Churchill Livingstone; 2000. p. 1025-41.
2. Rees J.K., Gray R.G., Swirsky D., et al. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet. 2:1986;1236-1241
3. Mayer R.J., Davis R.B., Schiffer C.A., et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N. Engl. J. Med. 331:1994;896-903
4. Buchner T., Hiddemann W., Wormann B., et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood. 93:1999;4116-4124
5. Stone R.M., Berg D.T., George S.L., et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl. J. Med. 332:1995;1671-1677
6. Rowe J.M., Andersen J.W., Mazza J.J., et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood. 86:1995;457-462
7. Lowenberg B., Suciu S., Archimbaud E., et al. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organization for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood. 90:1997;2952-2961
8. Godwin J.E., Kopecky K.J., Head D.R., et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (9031). Blood. 91:1998;3607-3615
9. Lowenberg B., Suciu S., Archimbaud E., et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J. Clin. Oncol. 16:1998;872-881
10. Velu T.D.L., Strickmans P. Daunorubicin in patients with relapsed and refractory acute non lymphocytic leukemia previously treated with anthracycline. Am J. Haematol. 27:1998;224
11. Estey E.H. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia. 14:2000;476-479
12. Lee S., Tallman M.S., Oken M.M., et al. Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia. Eastern Cooperative Oncology Group. Leukemia. 14:2000;1345-1348
13. Sievers EL, Larson R, Estey E, et al. Comparison of efficacy and safety of gemtuzumab ozogamicin (CMA-676) in patients less than 60 and greater or equal than 60 years of age with AML in first relapse years. Proc Am Soc Clin Oncol 2000;8a.
14. Tallman MS. New developments in targeted therapy for AML. ASCO Annual Educational Book; 2000. p. 110-21.
15. Sievers E.L., Appelbaum F.R., Spielberger R.T., et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 93:1999;3678-3684
16. Baer M.R., George S.L., Dodge R.K., et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood. 100:2002;1224-1232
17. Cutler EG, Bradford EH. Action of iron, cod-liver oil and arsenic on the globular richness of the blood. Am J Med Sci 1878;75.
18. Kwong Y.L., Todd D. Delicious poison: arsenic trioxide for the treatment of leukemia. Blood. 89:1997;3487-3488
19. Forkner C.E., Scott T.F.M. Arsenic as a therapeutic agent in chronic myelogenous leukemia. JAMA. 97:1931;3
20. Sears D.A. History of the treatment of chronic myelocytic leukemia. Am J. Med. Sci. 296:1988;85-86
21. Sun H.D., Ma L., Hu X.C., Zhang T.D., et al. Ai-Lin 1 treated 32 cases of acute promyelocytic leukemia. Chin J. Integr. Chin West Med. 12:1992;170-172
22. Zhang P., Wang S.Y., Hu X.H., et al. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J. Haematol. 17:1996;58-62
23. Shen Z.X., Chen G.Q., Ni J.H., et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 89:1997;3354-3360
24. Soignet S.L., Maslak P., Wang Z.G., et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl. J. Med. 339:1998;1341-1348
25. Soignet S.L., Frankel S.R., Douer D., et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J. Clin. Oncol. 19:2001;3852-3860
26. Zhu J., Koken M.H., Quignon F., et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 94:1997;3978-3983
27. Shao W., Fanelli M., Ferrara F.F., et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J. Natl. Cancer Inst. 90:1998;124-133
28. Roboz G.J., Dias S., Lam G., et al. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood. 96:2000;1525-1530
29. Miller W.H. Jr., Schipper H.M., Lee J.S., et al. Mechanisms of action of arsenic trioxide. Cancer Res. 62:2002;3893-3903
30. Zhu X.H., Shen Y.L., Jing Y.K., et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J. Natl. Cancer Inst. 91:1999;772-778
31. Ishitsuka K., Ikeda R., Utsunomiya A., et al. Arsenic trioxide induces apoptosis in HTLV-I infected T-cell lines and fresh adult T-Cell leukemia cells through CD95 or tumor necrosis factor alpha receptor independent caspasc activation. Leuk. Lymphoma. 43:2002;1107-1114
32. Lehmann S., Bengtzen S., Paul A., Christensson B., Paul C. Effects of arsenic trioxide (As2O3) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity. Eur. J. Haematol. 66:2001;357-364
33. Jing Y., Wang L., Xia L., et al. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood. 97:2001;264-269
34. Munshi N.C., Tricot G., Desikan R., et al. Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia. 16:2002;1835-1837
35. Hussein M.A. Trials of arsenic trioxide in multiple myeloma. Cancer Control. 10:2003;370-374
36. Soignet S.L., Novick S., Bienvenu B., et al. Arsenic trioxide (AS2O3): a dose-ranging and clinical pharmacologic study in patients with advanced hematologic cancers. Cancer Res. 41:2000;543. (abstract 3462)
37. Dutcher J.P., Wiernik P.H., Novik Y., et al. Major hematologic response in a patient with myelodysplastic syndrome (MDS) to Arsenic Trioxide (ATO). Blood. 96:2000;260b. (abstract 485b)
38. List A., Beran M., DiPersio J., et al. Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia. 17(8):2003;1499-1507
39. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br. J. Haematol. 78:1991;325-329
40. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 103:1985;620-625
41. Cryns V., Yuan J. Proteases to die for. Genes Dev. 12:1998;1551-1570
42. Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol. Cell. 9:2002;459-470
43. Thornberry N.A., Lazebnik Y. Caspases: enemies within. Science. 281:1998;1312-1316
44. Campos L., Guyotat D., Archimbaud E., et al. Clinical significance of multidrug resistance protein p-glycoprotein expression in acute non-lymphoblastic leukemia cells at diagnosis. Blood. 79:1992;473-476
45. Cheson B.D., Cassileth P.A., Head D.R., et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J. Clin. Oncol. 8:1990;813-819
46. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin. Trials. 10:1989;1
47. Soignet S., Calleja E., Cheung N-K., et al. A phase I study of arsenic trioxide (ATO) in patients with solid tumors. Proc. Am Soc. Clin. Oncol. 18:1999;878
48. Huang M.J., Hsieh R.K., Lin C.P., et al. The cytotoxicity of arsenic trioxide to normal hematopoietic progenitors and leukemic cells is dependent on their cell-cycle status. Leuk. Lymphoma. 43:2002;2191-2199
49. Pallis M., Turzanski J., Higashi Y., et al. p-Glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype. Leuk. Lymphoma. 43:2002;1221-1228
50. Arceci R.J. Clinical significance of p-glycoprotein in multidrug resistance malignancies. Blood. 81:1993;2215-2222
51. den Boer M.L., Pieters R., Kazemier K.M., et al. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, p-glycoprotein expression, and drug resistance in childhood leukemia. Blood. 91:1998;2092-2098
52. Liu Q., Hilsenbeck S., Gazitt Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase 8 or caspase 9 and synergy with APO2/TRAIL. Blood. 101:2003;4078-4087
53. Akao Y., Yamada H., Nakagawa Y. Arsenic-induced apoptosis in malignant cells in vitro. Leuk Lymphoma. 37:2000;53-63
54. Camacho L.H., Soignet S.L., Chanel S., et al. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J. Clin. Oncol. 18:2000;2620-2625
55. Jing H.M., Yukihiro S., Ke X.Y., et al. Effect of arsenic trioxide on different cell lines derived from chronic myeloid leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 10:2002;413-418
56. Mahieux R., Pise-Masison C., Gessain A., et al. Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase 3-dependent mechanism involving Bcl-2 cleavage. Blood. 98:2001;3762-3769
57. Kitamura K., Minami Y., Yamamoto K., et al. Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis. Leukemia. 14:2000;1743-1750
58. Ashkenazi A., Dixit V.M. Death receptors: signaling and modulation. Science. 281:1998;1305-1308
59. Lacour S., Hammann A., Wotawa A., et al. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res. 61:2001;1645-1651
60. Mitsiades N., Mitsiades C.S., Poulaki V., et al. Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood. 99:2002;2162-2171
61. Adams J.M., Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 281:1998;1322-1326
62. Fenaux P., Chastang C., Chevret S., et al. A randomized comparison of all trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 94:1999;1192-1200
63. Munshi N.C., Tricot G., Desikan R., et al. Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia. 16:2002;1835-1837
64. Niu C., Yan H., Yu T., et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 94:1999;3315-3324
65. Soignet S., Frankel S., Tallman M., et al. U.S. Multicenter trial of arsenic trioxide (ATO) in acute promyelocytic leukemia (APL). Blood. 94:1999;698a
66. Chen G.Q., Zhu J., Shi X.G., et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 88:1996;1052-1061
67. Bachleitner-Hofmann T., Gisslinger B., Grumbeck E., et al. Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia? Br. J. Haematol. 112:2001;783-786
68. Bahlis N.J., McCafferty-Grad J., Jordan-McMurry I., et al. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin. Cancer Res. 8:2002;3658-3668
69. Huang X. Potentiation of arsenic trioxide-induced apoptosis by retinoic acid in retinoic acid sensitive and resistant HL-60 myeloid leukemia cells. Chin Med. J. (Engl.). 113:2000;498-501
70. Sakurai T., Qu W., Sakurai M.H., et al. A major human arsenic metabolite, dimethylarsinic acid, requires reduced glutathione to induce apoptosis. Chem Res. Toxicol. 15:2002;629-637
71. Shen Y., Chen G., Cai X. Glutathione synthesis inhibitor enhances arsenic trioxide-induced apoptosis. Zhonghua Zhong Liu Za Zhi. 21:1999;259-261
72. Grad J.M., Bahlis N.J., Reis I., et al. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood. 98:2001;805-813
73. Gartenhaus R.B., Prachand S.N., Paniaqua M., et al. Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state. Clin. Cancer Res. 8:2002;566-572
74. Yuksel S., Saydam G., Uslu R., et al. Arsenic trioxide and methylprednisolone use different signal transduction pathways in leukemic differentiation. Leuk Res. 26:2002;391-398
75. Estrov Z., Manna S.K., Harris D., et al. Phenylarsine oxide blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells. Blood. 94:1999;2844-2853
76. Oetken C., von Willebrand M., Autero M., et al. Phenylarsine oxide augments tyrosine phosphorylation in hematopoietic cells. Eur. J. Haematol. 49:1992;208-214
77. Konig A., Wrazel L., Warrell R.P. Jr., et al. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood. 90(2):1997;562-570
78. Soignet S.L., Tong W.P., Hirschfeld S., et al. Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia. Cancer Chemother Pharmacol. 44:1999;417-421